ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2024 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 4.900-5.050 for the period, compared to the consensus estimate of 4.720. The company issued revenue guidance of $594.0 million-$602.0 million, compared to the consensus revenue estimate of $590.3 million.

Analysts Set New Price Targets

ANIP has been the topic of a number of research reports. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Raymond James lifted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective for the company. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $58.38 on Friday. The business has a 50-day moving average of $58.70 and a 200-day moving average of $61.58. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 49.90 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same period in the prior year, the company posted $1.06 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% compared to the same quarter last year. As a group, equities research analysts anticipate that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.